One company is determined to improve drug development success rates, and its cell simulation platform is already being used ...

Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.

A change in FTC leadership would likely see a relaxation of antitrust enforcement and an increase in biopharma M&A activity.

Lundbeck has completed the acquisition of all outstanding shares of Longboard Pharmaceuticals, to bolster the neuro-rare disease sector.

J&J is seeking approval of TREMFYA for paediatric conditions with the submission of two sBLA to the US Food and Drug Administration.

Olema Oncology and Novartis have signed a clinical trial collaboration and supply agreement for a Phase III trial in metastatic breast cancer.

Novartis has entered a worldwide licence and partnership agreement with PTC Therapeutics for the development of PTC518.

Turkiye’s pharmaceutical industry has grappled with significant economic challenges such as the frequent upward revision of the pharmaceutical Euro exchange rate.

The research team at UQ has secured a grant of $344,000 from the National Foundation for Medical Research and Innovation.

The MHRA has also granted approval to Faron Pharmaceuticals to conduct the BEXMAB trial of Clevegen in the UK.

CBC Group has completed the strategic acquisition of UCB's mature neurology and allergy business in China for $680m.

The EMA’s CHMP has endorsed expanding the use of Palforzia to toddlers aged one to three years with peanut allergies.